InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,340.00
(
0.39%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.97
(
0.64%
)
Bitcoin
61,426.95
(
-0.30%
)
Post# of 426269
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ziploc_1

Send PM Follow Ignore
Followers 62
Posts 7553
Boards Moderated 1
Alias Born 01/02/2003

ziploc_1

Re: Tatsumaki post# 420101

Wednesday, 01/10/2024 12:16:18 PM

Wednesday, January 10, 2024 12:16:18 PM

Post# of 426269
The Q4 2023 report makes clear that Amarin has $300 million plus in cash and a positive cash flow...It also indicates that Amarin has an accepted product(Vascepa) in a vibrant market in the US and in ROW...with significant potential to become a blockbuster drug.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News
InvestorsHub NewsWire

VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM

North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM

Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM

POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM

HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM

Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM

Start posting your company's news
Only $200 per official company press release!